Evaluation of Clinical Efficiency of Cardioprotective Therapy in Patients with Acute Myocardial Infarction

Aim. To evaluate the efficiency of cardioprotective therapy using intravenous metoprolol in combination with a high dose of atorvastatin in the prevention of myocardial remodeling (MR) and heart failure (HF) in patients with acute ST-segment elevation myocardial infarction (STEMI).
Material AND methods. A prospective study included 100 STEMI patients who underwent primary percutaneous intervention (PCI). Depending on the regimens of drug cardioprotection, three groups of patients were formed: the first (2014–2015) — 34 patients who received 80 mg atorvastatin as a part of the basic therapy on the first day of STEMI, then 20–40 mg/day for 30 days. The second group (2017–2018) — 34 patients who received atorvastatin 80 mg/day for a month from the onset of STEMI. The third group (2018–2019) — 32 patients who received intravenous metoprolol tartrate (5–15 mg) and atorvastatin 80 mg/day before PCI for a month from the onset of STEMI. On days 1 and 2 of STEMI and one month later, patients were assessed for serum levels of cardiac biomarkers; on the 1st, 7th days and one month later, echocardiographic studies (EchoCG) were performed. At the end of the observation, clinical and imaging outcomes (MR and HF) were assessed, which were compared with the dynamics of biomarkers between the groups of patients.
Results. The combined use of atorvastatin 80 mg/day for a month from the onset of STEMI and a single intravenous injection of metoprolol tartrate (5–15 mg) in the acute phase of STEMI before PCI showed the most significant effects in the prevention of the development of structural and functional myocardial disorders and clinically severe heart failure, and also caused the minimal serum activity of cardiomarkers in the third group of patients in comparison with the first and second groups of patients without this drug combination. Also, correlations between biomarkers and echocardiography indicators were established in the third group of patients who received cardioprotective therapy.
Conclusion. The combined use of high-dose atorvastatin for a month with a single intravenous injection of metoprolol tartrate in acute STEMI before PCI prevents the formation of MR and clinically significant HF in the post-infarction period. Comprehensive dynamic assessment of cardiac biomarkers and echocardiography parameters within a month after post-STEMI is a highly informative tools for monitoring the efficiency of cardioprotective therapy.

1. Martsevich SYu, Kutishenko NP, Sichinava DP, Kalaydzhyan EP, Kasparova EA, Zagrebelnyy AV, et al. The Main Cardiovascular Complications and Mortality Rates During the First One and a Half Years after Acute Myocardial Infarction: Data from the Prospective Outpatient Registry PROFILE-IM. Rational Pharmacotherapy in Cardiology. 2020;16(3):432–438. (In Russ.) https://doi.org/10.20996/1819-6446-2020-06-11

2. Galli A., Lombardi F. Postinfarct Left Ventricular Remodelling: A Prevailing Cause of Heart Failure. Cardiol Res Pract. 2016:2579832. PMID: 26989555. https://doi.org/10.1155/2016/2579832

3. Gabriel-Costa D. The pathophysiology of myocardial infarction-induced heart failure. Pathophysiology. 2018; 25 (4): 277–284. PMID: 29685587. https://doi.org/10.1016/j.pathophys.2018.04.003

4. Astrakhantseva ID, Urvantseva IA, Vorob’yev AS, Nikolaev KY. Pathophysiological and Clinical Aspects of High-Dose Atorvastatin Cardioprotection in Patients with Acute Coronary Syndrome. Ateroscleroz. 2018;14(3):78–83. (In Russ.) https://doi.org/10.15372/ATER20180312

5. Cannon C.P., Braunwald E., McCabe C.H., Rader J.D., Rouleau J.L., Belder R., et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350 (15):1495–504 PMID: 15007110. https://doi.org/10.1056/NEJMoa040583

6. Davidson S.M., Ferdinandy P., Andreadou I., Botker H.E., Heusch G., Ibanez B., et al. Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury. J Am Coll Cardiol. 2019;73(1)89–99. PMID: 30621955. https://doi.org/10.1016/j.jacc.2018.09.086.

7. Giblett J. P., Bulluck H. Cardioprotection for Acute MI in Light of the CONDI2/ERIC-PPCI Trial: New Targets Needed. Interv Cardiol. 2020;15: e13. PMID: 32944081. https://doi.org/10.15420/icr.2020.01

8. Rossello X, Lobo-Gonzalez M, Ibanez B. Editor’s choice – pathophysiology and therapy of myocardial ischaemia/reperfusion syndrome. Eur Heart J Acute Cardiovasc Care. 2019;8(5):443–456. PMID: 31172789 https://doi.org/10.1177/2048872619845283

9. García-Prieto J, Villena-Gutierrez R, Gomez M, Bernardo E, PunGarcía A, García-Lunar I, et al. Neutrophil stunning by metoprolol reduces infarct size. Nat Commun. 2017;8:14780. PMID: 28416795 https://doi.org/10.1038/ncomms14780

10. Lobo-Gonzalez M, Galán-Arriola C, Rossello X, González-Del-Hoyo M, Vilchez JP, Higuero-Verdejo MI, et al. Metoprolol blunts the timedependent progression of infarct size. Basic Res Cardiol. 2020;115(5):55. PMID: 32748088 https://doi.org/10.1007/s00395-020-0812-4

11. Astrakhantseva ID, Urvantseva IA, Nikolaev KYu. The Use of Intravenous Forms of Beta-Blockers in Acute Coronary Syndrome. Ateroscleroz. 2017;13(2):50–54. (In Russ.).

12. Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S, et al. Early intravenous beta-blockers in patients with acute coronary syndrome – a meta-analysis of randomized trials. Int J Cardiol. 2013;168(2):915–921. PMID: 23168009; PMCID: PMC4104797. https://doi.org/10.1016/j.ijcard.2012.10.050.

13. Ibanez B, Macaya C, Sanchez-Brunete V, Pizarro G, Fernandez-Friera L, Mateos A, et al. Effect of early metoprolol on infarct size in STsegment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARDCNIC) Trial. Circulation. 2013;128(14):1495–1503. PMID: 24002794 https://doi.org/10.1161/CIRCULATIONAHA.113.003653

14. Roolvink V, Ibanez B. Ottervanger JP, Pizarro G, van Royen N, Mateos A, et al. Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. J Am Coll Cardiol. 2016;67(23):2705–2715. PMID: 27050189 https://doi.org/10.1016/j.jacc.2016.03.522

15. Roolvink V, Ottervanger JP, Ibanez B, Dambrink JH, Gosselink M, Kedhi E, et al. One-year clinical outcome of early administration of intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary reperfusion. EuroIntervention. 2018;14(6):688–691. PMID: 29155386 https://doi.org/10.4244/EIJ-D-17-00776

16. Newby LK. Intravenous Beta-Blockers for Cardioprotection in STEMI: The Saga Continues. J Am Coll Cardiol. 2016;67(23):2716–2718. PMID: 27050188 https://doi.org/10.1016/j.jacc.2016.03.532

17. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. PMID: 28886621 https://doi.org/10.1093/eurheartj/ehx393

18. Staroverov II, Shakhnovich RM, Gilyarov MYu, Komarov AL, Konstantinova EV, Panchenko EP, et al. Eurasian Clinical Guidelines on Diagnosis and Treatment of Acute Coronary Syndrome With St Segment Elevation (STEMI). Eurasian Heart Journal. 2020;(1):4–77. (In Russ.) https://doi.org/10.38109/2225-1685-2020-1-4-77

19. Averkov OV, Duplyakov DV, Gilyarov MYu, Novikova NA, Shakhnovich RM, Yakovlev AN. 2020 Clinical practice guidelines for Acute STsegment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):251–310. (in Russ.) https://doi.org/10.15829/1560-4071-2020-4103

20. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg P, James S, Atar D. Badano L, Blömstrom-Lundqvist C, Borger M, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–2619. PMID: 22922416 https://doi.org/10.1093/eurheartj/ehs215

21. Flachskampf FA, Schmid M, Rost С, Achenbach S, Demaria AN, Daniel WG. Cardiac imaging after myocardial infarction. Eur Heart J. 2011;32(3):272–283. PMID: 21163851 https://doi.org/10.1093/eurheartj/ehq446

22. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248–2261. PMID: 17984166 https://doi.org/10.1056/NEJMoa0706201

23. Hirayama A, Kusuoka H, Yamamoto H, Sakata Y, Asakura M, Higuchi Y, et al. Serial changes in plasma brain natriuretic peptide concentration at the infarct and non-infarct sites in patients with left ventricular remodelling after myocardial infarction. Heart. 2005;91(12):1573–1577. PMID: 15774610 http://dx.doi.org/10.1136/hrt.2004.049635

24. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003;107(22):2786–2792. PMID: 12771003 https://doi.org/10.1161/01.CIR.0000070953.76250.B9